298 related articles for article (PubMed ID: 33651110)
1. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
Socal MP; Bai G; Anderson GF
JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
[TBL] [Abstract][Full Text] [Related]
2. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
Song H; Adamson A; Mostaghimi A
JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
[TBL] [Abstract][Full Text] [Related]
3. Influence of pharmaceutical marketing on Medicare prescriptions in the District of Columbia.
Wood SF; Podrasky J; McMonagle MA; Raveendran J; Bysshe T; Hogenmiller A; Fugh-Berman A
PLoS One; 2017; 12(10):e0186060. PubMed ID: 29069085
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
5. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
6. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
7. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
[TBL] [Abstract][Full Text] [Related]
8. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
Bazalo G; Weiss RC
Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
[TBL] [Abstract][Full Text] [Related]
9. Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries.
Sumarsono A; Sumarsono N; Das SR; Vaduganathan M; Agrawal D; Pandey A
JAMA Netw Open; 2020 Feb; 3(2):e200181. PubMed ID: 32108893
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
11. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
12. Opioid Prescriptions by Pain Medicine Physicians in the Medicare Part D Program: A Cross-Sectional Study.
Goel V; Moran B; Kaizer AM; Sivanesan E; Patwardhan AM; Ibrahim M; DeWeerth JC; Shannon C; Shankar H
Anesth Analg; 2021 Jun; 132(6):1748-1755. PubMed ID: 33591120
[TBL] [Abstract][Full Text] [Related]
13. Measuring economic impact of applying daily average consumption limits.
Flavin BM; Nishida LM; Karbowicz SH; Renner ME; Leonard RJ
J Manag Care Pharm; 2014 Feb; 20(2):159-64. PubMed ID: 24456317
[TBL] [Abstract][Full Text] [Related]
14. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
16. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
[TBL] [Abstract][Full Text] [Related]
17. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
18. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
Socal MP; Bai G; Anderson GF
JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
[TBL] [Abstract][Full Text] [Related]
19. Sources of regional variation in Medicare Part D drug spending.
Donohue JM; Morden NE; Gellad WF; Bynum JP; Zhou W; Hanlon JT; Skinner J
N Engl J Med; 2012 Feb; 366(6):530-8. PubMed ID: 22316446
[TBL] [Abstract][Full Text] [Related]
20. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
